Loading…

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases

Optimization of a 7-azaindole-3-acetic acid CRTh2 receptor antagonist chemotype derived from high throughput screening furnished a highly selective compound NVP-QAV680 with low nM functional potency for inhibition of CRTh2 driven human eosinophil and Th2 lymphocyte activation in vitro. The molecule...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2013-11, Vol.21 (21), p.6582-6591
Main Authors: Sandham, David A., Arnold, Nicola, Aschauer, Heinrich, Bala, Kamlesh, Barker, Lucy, Brown, Lyndon, Brown, Zarin, Budd, David, Cox, Brian, Docx, Cerys, Dubois, Gerald, Duggan, Nicholas, England, Karen, Everatt, Brian, Furegati, Marcus, Hall, Edward, Kalthoff, Frank, King, Anna, Leblanc, Catherine J., Manini, Jodie, Meingassner, Josef, Profit, Rachael, Schmidt, Alfred, Simmons, Jennifer, Sohal, Bindi, Stringer, Rowan, Thomas, Matthew, Turner, Katharine L., Walker, Christoph, Watson, Simon J., Westwick, John, Willis, Jennifer, Williams, Gareth, Wilson, Caroline
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Optimization of a 7-azaindole-3-acetic acid CRTh2 receptor antagonist chemotype derived from high throughput screening furnished a highly selective compound NVP-QAV680 with low nM functional potency for inhibition of CRTh2 driven human eosinophil and Th2 lymphocyte activation in vitro. The molecule exhibited good oral bioavailability in the rat, combined with efficacy in rodent CRTh2-dependent mechanistic and allergic disease models and was suitable for clinical development.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2013.08.025